ARTIMPLANT INTERIM REPORT JANUARY – MARCH 2009

Västra Frölunda, Sweden, May 5, 2009

• Net revenue for the first quarter amounted to SEK 4.8 million (2.1)*
• The net loss for the first quarter totaled SEK 4.5 million (6.2)
• Earnings per share for the first quarter amounted to SEK -0.08 (-0.10)
• Sales of Artelon® Spacer totaled SEK 3.5 million (1.3)
• Sales of Artelon® Tissue Reinforcement amounted to SEK 1.3 million (0.8)
• Spacer agreements with Small Bone Innovations have been made non-exclusive and Artimplant's margin per unit sold has increased significantly

Events after the period-end
• The Schulthess Clinic in Zurich has been granted clearance by Swissmedic to commence a clinical investigation of treatment of lumbar facet joints using an Artelon® implant.
• The agreement with Biomet Sports Medicine has been revised, giving Artimplant a better margin in return for responsibility for clinical market studies.

N.B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will present this report at the Annual Meeting on May 5, 2009, at 5pm, Central European Time (GMT+1). The presentation will be published on the Company's website after the meeting. No telephone conference will be held by reason of this report. For further information and full interim report see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year